[Translation] A randomized, open-label, single-dose, two-formulation, two-sequence, two-period, self-crossover controlled design was used to evaluate the bioequivalence of a single topical application of the test formulation lipofusine cream and the reference formulation lipofusine cream (trade name: EMLA®) in healthy participants in a Chinese trial under fasting conditions.
主要目的:观察健康试验参与者空腹状态下单剂量外用受试制剂利丙双卡因乳膏(规格:5g:利多卡因125mg与丙胺卡因125mg,生产厂家:上海小方制药股份有限公司)后血药浓度的经时过程,估算相应的药代动力学参数;并以利丙双卡因乳膏(商品名:EMLA®,规格:1g:利多卡因25mg,丙胺卡因25mg,持证商:Aspen Pharma Trading Limited)为参比制剂,进行人体生物等效性正式试验,为该药注册申报和临床应用提供参考依据。
次要目的:观察试验参与者空腹状态下外用受试制剂和参比制剂的安全性。
[Translation] Primary Objective: To observe the time-dependent plasma concentrations of the test formulation, lidocaine cream (5g: lidocaine 125mg and prilocaine 125mg, manufacturer: Shanghai Xiaofang Pharmaceutical Co., Ltd.), after a single dose in fasting healthy participants, and to estimate the corresponding pharmacokinetic parameters. A formal human bioequivalence study was conducted using lidocaine cream (trade name: EMLA®, 1g: lidocaine 25mg and prilocaine 25mg, licensee: Aspen Pharma Trading Limited) as the reference formulation, providing a reference for the drug's registration and clinical application.
Secondary Objective: To observe the safety of the test and reference formulations after fasting in participants.